Publicacións nas que colabora con Mar Tormo Díaz (11)

2017

  1. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

    Leukemia and Lymphoma, Vol. 58, Núm. 1, pp. 145-152

2014

  1. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

    Cancer, Vol. 120, Núm. 24, pp. 3958-3964

  2. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial

    Journal of Clinical Oncology, Vol. 32, Núm. 15, pp. 1595-1604

2010

  1. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

    Haematologica, Vol. 95, Núm. 1, pp. 87-95

  2. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group

    Haematologica, Vol. 95, Núm. 4, pp. 589-596

2008

  1. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the programa Español de tratamiento en hematología pediatric-based protocol ALL-96

    Journal of Clinical Oncology, Vol. 26, Núm. 11, pp. 1843-1849

2007

  1. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

    European Journal of Haematology, Vol. 78, Núm. 2, pp. 102-110

2006

  1. Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes

    Medicina Clinica, Vol. 126, Núm. 2, pp. 41-46

2005

  1. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial

    Haematologica, Vol. 90, Núm. 10, pp. 1346-1356

  2. Prevalencia y significado pronóstico de los marcadores mieloides en adultos con leucemia aguda linfoblástica de alto riesgo

    Medicina Clinica, Vol. 125, Núm. 7, pp. 241-246

2002

  1. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial

    Haematologica, Vol. 87, Núm. 2, pp. 154-166